An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

被引:73
作者
Younossi, Zobair M. [1 ,2 ]
Stepanova, Maria [3 ]
Henry, Linda [3 ]
Nader, Fatema [3 ]
Hunt, Sharon [3 ]
机构
[1] Inova Fairfax Hosp, Dept Med, Ctr Liver Dis, Falls Church, VA USA
[2] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, 3300 Gallows Rd,Claude Moore Hlth Educ & Res Bldg, Falls Church, VA 22042 USA
[3] Ctr Outcomes Res Liver Dis, Washington, DC USA
关键词
QUALITY-OF-LIFE; GENOTYPE; INFECTION; CHRONIC LIVER-DISEASE; WORK PRODUCTIVITY; VIRUS-INFECTION; LEDIPASVIR/SOFOSBUVIR REGIMENS; PLUS RIBAVIRIN; UNITED-STATES; SOFOSBUVIR; IMPACT;
D O I
10.1038/ajg.2016.99
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Interferon-and ribavirin (RBV)-containing regimens negatively impact patients' experience. The aim of this study was to quantify the impact of different anti-viral regimens for hepatitis C on patients' work productivity, fatigue, and other patient-reported outcomes (PROs). METHODS: The PRO data from multicenter multinational phase 3 clinical trials of sofosbuvir with and without interferon or RBV were retrospectively used. Treatment regimens were classified as interferon+RBV-containing, interferon-free RBV-containing, and interferon-free RBV-free. Four PRO instruments (SF-36, CLDQ-HCV, FACIT-F, and WPAI:SHP) were administered to subjects at baseline, during, and up to 24 weeks after treatment. RESULTS: We included 3,425 subjects with chronic hepatitis C infection with PRO data. Patients were 62.8% male, 62.2% treatment naive, 18.1% with cirrhosis, and 72.9% with HCV genotype 1. Of the study participants, 546 received interferon+RBV+sofosbuvir, 1,721 received sofosbuvir+RBV, and 1,158 received interferon-and RBV-free ledipasvir+sofosbuvir. At baseline, there were no difference in PROs between treatment groups (all P > 0.01). During treatment, the decrements in PROs were up to -23.6% for the interferon+RBV group, up to -7.0% in the sofosbuvir+RBV group, whereas there was an improvement of up to +11.6% in the interferon-free RBV-free group (all P < 0.0001). In multivariate analysis, the use of interferon was independently associated with up to -26.0% worsening of the PRO scores during treatment and the use of RBV with up to -9.0% worsening. After 12 weeks post-treatment, in patients with sustained virologic response-12, improvements were observed regardless of the regimen, and these improvements continued to increase by week 24 of follow-up. CONCLUSIONS: The use of interferon-and RBV-free regimens for HCV is associated with better patients' experience and work productivity during treatment.
引用
收藏
页码:808 / 816
页数:9
相关论文
共 40 条
[1]   Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Zeuzem, Stefan ;
Kwo, Paul ;
Chojkier, Mario ;
Gitlin, Norman ;
Puoti, Massimo ;
Romero-Gomez, Manuel ;
Zarski, Jean-Pierre ;
Agarwal, Kosh ;
Buggisch, Peter ;
Foster, Graham R. ;
Braeu, Norbert ;
Buti, Maria ;
Jacobson, Ira M. ;
Subramanian, G. Mani ;
Ding, Xiao ;
Mo, Hongmei ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Mangia, Alessandra ;
Marcellin, Patrick .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898
[2]   Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Reddy, K. Rajender ;
Nelson, David R. ;
Lawitz, Eric ;
Gordon, Stuart C. ;
Schiff, Eugene ;
Nahass, Ronald ;
Ghalib, Reem ;
Gitlin, Norman ;
Herring, Robert ;
Lalezari, Jacob ;
Younes, Ziad H. ;
Pockros, Paul J. ;
Di Bisceglie, Adrian M. ;
Arora, Sanjeev ;
Subramanian, G. Mani ;
Zhu, Yanni ;
Dvory-Sobol, Hadas ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Sulkowski, Mark ;
Kwo, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493
[3]   Predictors of health-related quality of life in patients with chronic liver disease [J].
Afendy, A. ;
Kallman, J. B. ;
Stepanova, M. ;
Younoszai, Z. ;
Aquino, R. D. ;
Bianchi, G. ;
Marchesini, G. ;
Younossi, Z. M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (05) :469-476
[4]  
[Anonymous], HLTH REL QUAL LIF
[5]   Predictors of Poor Mental and Physical Health Status Among Patients With Chronic Hepatitis C Infection: The Chronic Hepatitis Cohort Study (CHeCS) [J].
Boscarino, Joseph A. ;
Lu, Mei ;
Moorman, Anne C. ;
Gordon, Stuart C. ;
Rupp, Loralee B. ;
Spradling, Philip R. ;
Teshale, Eyasu H. ;
Schmidt, Mark A. ;
Vijayadeva, Vinutha ;
Holmberg, Scott D. .
HEPATOLOGY, 2015, 61 (03) :802-811
[6]   Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) [J].
Bourliere, Marc ;
Bronowicki, Jean-Pierre ;
de Ledinghen, Victor ;
Hezode, Christophe ;
Zoulim, Fabien ;
Mathurin, Philippe ;
Tran, Albert ;
Larrey, Dominique G. ;
Ratziu, Vlad ;
Alric, Laurent ;
Hyland, Robert H. ;
Jiang, Deyuan ;
Doehle, Brian ;
Pang, Phillip S. ;
Symonds, William T. ;
Subramanian, G. Mani ;
McHutchison, John G. ;
Marcellin, Patrick ;
Habersetzer, Francois ;
Guyader, Dominique ;
Grange, Jean-Didier ;
Loustaud-Ratti, Veronique ;
Serfaty, Lawrence ;
Metivier, Sophie ;
Leroy, Vincent ;
Abergel, Armand ;
Pol, Stanislas .
LANCET INFECTIOUS DISEASES, 2015, 15 (04) :397-404
[7]  
Brook RA, 2011, AM J MANAG CARE, V17, P657
[8]  
DiBonaventura Marco daCosta, 2011, J Med Econ, V14, P253, DOI 10.3111/13696998.2011.566294
[9]   Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection [J].
Gerber, Lynn ;
Estep, Michael ;
Stepanova, Maria ;
Escheik, Carey ;
Weinstein, Ali ;
Younossi, Zobair M. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (01) :156-+
[10]   A Review of Patient-Reported Outcome Labels in the United States: 2006 to 2010 [J].
Gnanasakthy, Ari ;
Mordin, Margaret ;
Clark, Marci ;
DeMuro, Carla ;
Fehnel, Sheri ;
Copley-Merriman, Catherine .
VALUE IN HEALTH, 2012, 15 (03) :437-442